Cancer最新文献

{"title":"Desmoid tumors: Old and new drugs for a rare and challenging disease.","authors":"Bernd Kasper","doi":"10.1002/cncr.35603","DOIUrl":"10.1002/cncr.35603","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":" ","pages":"e35603"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142611432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of tenosynovial giant tumors with colony-stimulating factor 1 receptor kinase inhibitors: When to start? When to stop? When to restart?","authors":"Jean-Yves Blay, Armelle Dufresne, François Gouin, Gualter Vaz, Mehdi Brahmi","doi":"10.1002/cncr.35635","DOIUrl":"10.1002/cncr.35635","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":" ","pages":"e35635"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global disparities in cancer care: Bridging the gap in affordability and access to medications between high and low-income countries.","authors":"Arafat H Tfayli, Laura N El-Halabi, Fadlo R Khuri","doi":"10.1002/cncr.35590","DOIUrl":"10.1002/cncr.35590","url":null,"abstract":"<p><strong>Background: </strong>Cancer remains a significant challenge for health care systems, despite notable progress in the field. These advancements have significant financial implications that disproportionately affect low-income countries. This review article aims to explore the present state of drug development, assessing the availability of drugs in different income countries, and proposing potential solutions to address the inequality in access to new cancer treatments.</p><p><strong>Methods: </strong>A search was conducted on MEDLINE and PubMed on October 2, 2023 and updated on December 14, 2023, limited to English language articles.</p><p><strong>Results: </strong>There is a projected rise in cancer cases worldwide, particularly in low-income countries where most cancer-related deaths are expected. Although the approval rate of cancer treatments has risen, their excessive cost and lack of affordability pose significant barriers to widespread access. Disparities in the costs of crucial cancer medications are influenced by geographic location and procurement connections. Potential solutions to address the inequity in drug distribution include sharing production secrets, implementing price discrimination, international funding, improved primary health care measures, and the implementation of cost-effective screening methods.</p><p><strong>Conclusion: </strong>Preventing, screening for, and treating cancer should be a global priority with minimal differences in access to therapy among various countries.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":" ","pages":"e35590"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Agreement of medical record abstraction and self-report of breast cancer treatment with an extended recall window.","authors":"Anne S Reiner, Julia A Knight, Esther M John, Charles F Lynch, Kathleen E Malone, Xiaolin Liang, Meghan Woods, James C Root, Jonine L Bernstein","doi":"10.1002/cncr.35459","DOIUrl":"10.1002/cncr.35459","url":null,"abstract":"<p><strong>Background: </strong>Medical record abstraction (MRA) and self-report questionnaires are two methods frequently used to ascertain cancer treatment information. Prior studies have shown excellent agreement between MRA and self-report, but it is unknown how a recall window longer than 3 years may affect this agreement.</p><p><strong>Methods: </strong>The Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study is a multicenter, population-based case-control study of controls with unilateral breast cancer individually matched to cases with contralateral breast cancer. Participants who were diagnosed with a first primary breast cancer from 1985 to 2008 before the age of 55 years completed a questionnaire that included questions on treatment. First primary breast cancer treatment information was abstracted from the medical record from radiation oncology clinic notes for radiation treatment and from systemic adjuvant treatment reports for hormone therapy and chemotherapy. Agreement between MRA and self-reported treatment was assessed with the kappa statistic and corresponding 95% confidence intervals (CIs).</p><p><strong>Results: </strong>A total of 2808 participants with MRA and self-reported chemotherapy treatment information, 2733 participants with MRA and self-reported hormone therapy information, and 2905 participants with MRA and self-reported radiation treatment information were identified. The median recall window was 12.5 years (range, 2.8-22.2 years). MRA and self-reported treatment agreement was excellent across treatment modalities (kappa_chemo, 98.5; 95% CI, 97.9-99.2; kappa_horm, 87.7; 95% CI, 85.9-89.5; kappa_rad, 97.9; 95% CI, 97.0-98.7). There was no heterogeneity across recall windows (p_chemo = .46; p_horm = .40; p_rad = .61).</p><p><strong>Conclusions: </strong>Agreement between self-reported and MRA primary breast cancer treatment modality information was excellent for young women diagnosed with breast cancer and was maintained even among women whose recall window was more than 20 years after diagnosis.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":" ","pages":"e35459"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141464525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of exercise therapy on chemotherapy delivery and response in primary breast cancer: A secondary analysis of a randomized trial.","authors":"Neil M Iyengar, Jessica M Scott, Jasme Lee, Jessica A Lavery, Katherine L Foug, Catherine P Lee, Meghan G Michalski, Su S Chun, Jenna Harrison, Chaya S Moskowitz, Lee W Jones","doi":"10.1002/cncr.35575","DOIUrl":"10.1002/cncr.35575","url":null,"abstract":"<p><strong>Background: </strong>Whether structured exercise therapy improves chemotherapy delivery, tolerability, and tumor response is unclear.</p><p><strong>Methods: </strong>This was a secondary analysis of a phase 2 trial investigating exercise therapy (n = 72) versus usual care (n = 72) in patients with primary breast cancer. Exercise therapy comprised individualized treadmill walking three times weekly for 20-50 minutes per session at 55%-100% of pretreatment exercise capacity. Chemotherapy delivery was assessed according to the relative dose intensity (RDI), tolerability was assessed according to patient-reported outcomes and blood laboratory values, and response was assessed based on the pathologic complete response rate in patients who received neoadjuvant chemotherapy.</p><p><strong>Results: </strong>In the exercise therapy group, 51 patients (71%) reached 100% RDI (median, 100%; interquartile range, 100%-100%) compared with 41 patients (57%) in the usual care group (median, 100%; interquartile range, 95%-100%; p = .08). Tolerability was similar in both groups; the rates of grade 3 or higher neutropenia and anemia were 22% versus 39% and 7% versus 10% in the exercise and usual care groups, respectively. In patients who received anthracyclines (n = 104), 41 (77%) had 100% chemotherapy RDI in the exercise therapy group versus 29 (57%) in the usual care group (p = .026). In the neoadjuvant chemotherapy subgroup (n = 51 tumors), the postneoadjuvant therapy (yp) pathologic complete response (ypT0ypN0) rate was 27% (95% confidence interval, 12%-50%) in the exercise therapy group compared with 28% (95% confidence interval, 13%-47%) in the usual care group (p > .9).</p><p><strong>Conclusions: </strong>In patients with primary breast cancer, exercise therapy was associated with improved delivery of anthracycline-based chemotherapy. Although exercise therapy was not significantly associated with tumor response, effects varied by tumor subtype (trial registration: Clinicaltrials.gov identifier NCT01943695).</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":" ","pages":"e35575"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen-deprivation therapy: A population-based assessment of adherence to therapeutic monitoring guidelines.","authors":"Ahmad Mousa, David-Dan Nguyen, Aly-Khan Lalani, Raj Satkunasivam, Khatereh Aminoltejari, Amanda Hird, Soumyajit Roy, Scott C Morgan, Shawn Malone, Andrea Kokorovic, Luke T Lavallée, Melissa Huynh, Bobby Shayegan, Di Maria Jiang, Geofrey Gotto, Rodney H Breau, Girish S Kulkarni, Alexandre Zlotta, Christopher J D Wallis","doi":"10.1002/cncr.35606","DOIUrl":"10.1002/cncr.35606","url":null,"abstract":"<p><strong>Background: </strong>Androgen-deprivation therapy (ADT) remains a cornerstone in treatment for patients with advanced prostate cancer. ADT is associated with several adverse effects, including osteoporosis, metabolic syndrome, and cardiovascular events, leading to guidelines recommending routine testing to monitor for these toxicities. There is a lack of data assessing adherence to these recommendations.</p><p><strong>Methods: </strong>The authors conducted a retrospective cohort study using administrative data from Ontario, Canada between 2008 and 2021. They identified all older men (aged 65 years and older) who received ADT for prostate cancer using comprehensive provincial health databases. The primary outcomes were the use of testing for lipids, dysglycemia (glucose), bone health serum, and bone density between 6 weeks before and 1 year after the initiation of ADT.</p><p><strong>Results: </strong>In total, 29,097 patients were examined, of whom 52.8% were prescribed ADT by urologists, 37.9% were prescribed ADT by radiation oncologists, 2.8% were prescribed ADT by medical oncologists, and 2.4% were prescribed ADT by other physicians. Adherence to guidelines was low: only 21.3% of patients received a bone density scan, 41.2% underwent bone health-related serum tests, 51.3% completed a lipid profile, and 65.9% underwent dysglycemia testing within 1 year of diagnosis. Overall, only 11.9% of patients received all of the recommended investigations. Adherence to testing did not appear to improve over time (2008-2021) or with guideline publication. Patient (age) and physician (specialty) factors had important associations with adherence to testing.</p><p><strong>Conclusions: </strong>Most patients receiving ADT for prostate cancer do not receive recommended testing to monitor for treatment-related toxicity. Further study is required to address barriers to therapeutic monitoring of men on ADT and to reduce treatment-associated adverse events.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":" ","pages":"e35606"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142454010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.","authors":"Eduardo Rodríguez-Arbolí, Rebeca Rodríguez-Veiga, Elena Soria-Saldise, Juan M Bergua, Teresa Caballero-Velázquez, Montserrat Arnán, Susana Vives, Josefina Serrano, Teresa Bernal, Pilar Martínez-Sánchez, Mar Tormo, Carlos Rodríguez-Medina, Pilar Herrera-Puente, Esperanza Lavilla-Rubira, Blanca Boluda, Evelyn Acuña-Cruz, Isabel Cano, Sara Cáceres, Juan Ballesteros, José Falantes, David Martínez-Cuadrón, José A Pérez-Simón, Pau Montesinos","doi":"10.1002/cncr.35618","DOIUrl":"10.1002/cncr.35618","url":null,"abstract":"<p><strong>Background: </strong>LAMVYX was a multicenter, single-arm, phase 2 trial designed to validate the safety and efficacy of CPX-351 in patients aged 60-75 years with newly diagnosed, secondary acute myeloid leukemia and to generate evidence on key issues not addressed in the preceding regulatory pivotal trial.</p><p><strong>Methods: </strong>The primary end point of the study was the complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate after induction. Eligible patients were recommended to undergo allogeneic hematopoietic stem cell transplantation after the first consolidation cycle. Alternatively, patients could undergo up to six maintenance cycles with CPX-351.</p><p><strong>Results: </strong>Twenty-nine patients (49%; 95% exact confidence interval [CI], 37%-62%) patients achieved a CR/CRi after one or two cycles of induction, with a measurable residual disease negativity rate of 67% as assessed by centralized, multiparameter flow cytometry. Among patients who had serial next-generation sequencing analyses available, clearance of somatic mutations that were present at diagnosis was achieved in 7 (35%). The median follow-up among survivors was 16.8 months (range, 8.7-24.3 months). The median event-free survival was 3.0 months (95% CI, 1.4-7.3 months), and the median overall survival was 7.4 months (95% CI, 3.7-12.7 months). In landmark analyses at day +100 from diagnosis, the 1-year overall and event-free survival rate among patients who underwent allogeneic hematopoietic stem cell transplantation was 70% (95% CI, 47%-100%) and 70% (95% CI, 47%-100%), respectively. The corresponding values were 89% (95% CI, 71%-100%) and 44% (95% CI, 21%-92%), respectively, for patients who entered the maintenance phase. No significant longitudinal changes were observed in severity index or quality-of-life visual analog scale scores.</p><p><strong>Conclusions: </strong>The current data provide novel insights that might inform the clinical positioning and optimal use of CPX-351, complementing previous results (ClinicalTrials.gov identifier NCT04230239).</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":" ","pages":"e35618"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142542323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comprehensive approach to defining the cutoff value of oligometastasis in head and neck squamous cell carcinoma.","authors":"Diako Berzenji, Olivier R G Oude Booijink, Renske Gahrmann, Hetty Mast, Marta E Capala, Sjors A Koppes, Esther van Meerten, Bernd Kremer, Robert Jan Baatenburg de Jong, Marinella P J Offerman, Jose A Hardillo","doi":"10.1002/cncr.35632","DOIUrl":"10.1002/cncr.35632","url":null,"abstract":"<p><strong>Background: </strong>Patients with limited distant metastatic disease, also known as oligometastasis, show better survival rates than polymetastatic patients, and may be amenable for curative-intent treatment. The definition of oligometastasis, however, is unknown, and no quantitative analyses on the cutoff value for oligometastasis have been performed before. This study aims to derive specific threshold values for the number of metastases and affected locations that defines oligometastatic disease in head and neck squamous cell carcinoma.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted including all patients diagnosed with distant metastases between 2006 and 2021. For each patient, the number of distant metastases and affected locations was recorded on the basis of the available imaging at the time of diagnosis. Cox regression analyses and a machine-learning k-means algorithm were used to determine threshold values.</p><p><strong>Results: </strong>A total of 384 patients untreated for their metastatic foci were analyzed. Most patients (n = 207; 53.9%) had metastasis to one anatomic location, followed by metastases in two anatomic locations (n = 62; 16.1%). The majority of patients had ≥9 metastatic foci (n = 174; 45.3%), followed by one focus (n = 74; 19.3%) and two foci (n = 32; 8.3%). Cox regression and machine-learning k-means models showed that although the number of metastases did not predict survival, the number of affected locations did significantly (p < .001), by identifying a threshold of two locations.</p><p><strong>Conclusions: </strong>Contrary to the prevalent dogma, the definition of oligometastasis should not be defined by the number of metastases but rather by the number of affected locations, with a maximum number of affected locations set at two.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":" ","pages":"e35632"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"American Society of Clinical Oncology guideline update on palliative care for patients with cancer: Addressing the reality gap.","authors":"Fionnuala Crowley, Cardinale B Smith, Robert M Arnold, Debora Afezolli","doi":"10.1002/cncr.35656","DOIUrl":"10.1002/cncr.35656","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":" ","pages":"e35656"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of a couple-based intervention addressing sexual concerns for breast cancer survivors: Results of a randomized controlled trial.","authors":"Jennifer Barsky Reese, Stephen J Lepore, Kristen A Sorice, Lauren A Zimmaro, Jill Hasler, Elizabeth Handorf, Mary B Daly, Alexandra K Zaleta, Kelly Westbrook, Laura S Porter","doi":"10.1002/cncr.35685","DOIUrl":"10.1002/cncr.35685","url":null,"abstract":"<p><strong>Background: </strong>Sexual concerns are common and problematic for breast cancer survivors. Partner and relationship factors often play a key role in determining survivors' sexual adjustment, making it likely that couple-based interventions that integrate survivors' partners could be especially promising for addressing survivors' sexual concerns. Yet few such interventions have been tested. The objective of this study was to evaluate the efficacy of the Intimacy Enhancement (IE) intervention, a four-session, couple-based intervention addressing breast cancer survivors' sexual concerns by telephone in a randomized controlled trial.</p><p><strong>Methods: </strong>Female posttreatment breast cancer survivors reporting sexual concerns and their intimate partners (N = 120 couples; 240 participants) were randomized either to the IE intervention or to Living Healthy Together (LHT), an active control intervention of equivalent length. Outcomes (measured at baseline, postintervention, and at 3 and 6 months postintervention) included breast cancer survivors' sexual function (primary), partners' sexual function (secondary), and survivors' and partners' psychosocial and relationship outcomes (secondary). Mixed linear regression models examined intervention effects on outcomes at all follow-ups.</p><p><strong>Results: </strong>Model-based estimates of intervention effects showed greater improvements in survivors' overall sexual function, sexual satisfaction, arousal, lubrication, and orgasm at postintervention (p < .05). Effects on survivors' 3-month and 6-month sexual functioning or other secondary outcomes were minimal. Most couples completed all IE sessions (97%) and LHT (92%), and satisfaction ratings were high.</p><p><strong>Conclusions: </strong>Compared with an active control intervention, the IE intervention had significant short-term benefits for survivors' sexual function. Efforts may be needed to increase the longevity of the positive effects, such as more frequent or adjunctive treatments.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":" ","pages":"e35685"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142790567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}